ENTITY
Bristol-Myers Squibb

Bristol-Myers Squibb (BMY UN)

2
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol Myers Squibb focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
18 Dec 2018 17:35

Taisho Frontrunner to Acquire BMS’s French OTC Business

Event – Bristol Myers Squibb Co (BMY US)'s  French OTC business UPSA has been on the block since June 2018. According to a December 17, 2018...

03 Dec 2018 08:00

Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement

Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...

Logo
421 Views
Share
31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
530 Views
Share
02 Oct 2018 06:24

Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene

Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...

Logo
705 Views
Share
bullishBeiGene
31 Jul 2018 06:02

BeiGene IPO Preview: Lucrative Lifesavers

BeiGene (BGNE US) is set to become the first overseas listed biotech firm to seek a secondary listing in Hong Kong, under the city’s newly revamped...

Logo
559 Views
Share
x